Stable Cash Flow, New Modalities Key To SK Bio’s Journey To Big, Balanced Biotech

South Korea's SK Biopharmaceuticals unveils a new long-term road map, or "financial story", which involves generating substantial cash flow and expansion into new modalities with the ultimate goal of becoming a “balanced, big biotech.”